Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Overview
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development
Argenx SE
Biogen Inc
Cellenkos Inc
GeNeuro SA
Hall Biopharma Co Ltd
Immupharma Plc
Johnson & Johnson
Octapharma AG
Pfizer Inc
Sanofi
Takeda Pharmaceutical Co Ltd
UCB SA
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Drug Profiles
batoclimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
CK-0803 - Drug Profile
Product Description
Mechanism Of Action
History of Events
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
forigerimod acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
hyaluronidase (recombint, human) + immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
M-254 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-06755347 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rituximab - Drug Profile
Product Description
Mechanism Of Action
History of Events
rozanolixizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAR-445088 - Drug Profile
Product Description
Mechanism Of Action
History of Events
temelimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Dormant Projects
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Discontinued Products
Chronic Inflammatory Demyeliting Polyneuropathy (CIDP) - Product Development Milestones
Featured News & Press Releases
Nov 16, 2021: Zai Lab announces first patient dosed in greater Chi in global registratiol clinical trial of efgartigimod in CIDP
Oct 08, 2021: argenx to highlight potential first-in-class FcRn antagonist Efgartigimod at upcoming Neuromuscular Meetings
Sep 01, 2021: Harbour BioMed announces IND approval for phase II trial of Anti-FcRn Batoclimab in chronic inflammatory demyeliting polyneuropathy in Chi
Feb 12, 2021: U.S. FDA approves PANZYGA for the treatment of adults with Chronic Inflammatory Demyeliting Polyneuropathy (CIDP)
Feb 02, 2021: argenx issues statement concerning Efgartigimod
Feb 01, 2021: Argenx announces “GO” decision in adhere trial of Efgartigimod in chronic inflammatory demyeliting polyneuropathy following interim alysis
May 18, 2020: Fil results from the ProCID study of efficacy and safety of 3 different dosages of Panzyga (NewGam) in patients with chronic inflammatory demyeliting polyneuropathy (CIDP) presented at AAN 2020
Feb 19, 2019: Gliknik to receive $15 million milestone payment from Pfizer following clinical progress with PF-06755347, previously known as GL-2045
Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data
Feb 22, 2018: GeNeuro receives Orphan Drug Desigtion from the US FDA for GNbAC1 in chronic inflammatory demyeliting polyneuropathy (CIDP)
Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Desigtion From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Argenx SE, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Biogen Inc, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Cellenkos Inc, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by HanAll Biopharma Co Ltd, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Immupharma Plc, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Johnson & Johnson, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Sanofi, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by UCB SA, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products, 2022